SOFT TISSUE SARCOMA

This early-phase study tested a drug called olaparib together with radiation therapy for people with advanced soft-tissue sarcoma that couldn't be removed by surgery. The main goal was to find the safest dose of olaparib and see how many patients had serious side effects. A total…

This early-phase trial tested the safety of adding the drug navtemadlin to standard radiation therapy before surgery for soft tissue sarcoma. The goal was to find the best dose and see if the combination could shrink tumors, making surgery easier. 39 patients with intermediate or…

This study tested a new drug (LVGN6051) combined with an existing drug (anlotinib) in 39 adults with advanced soft tissue sarcoma that had not responded to other treatments. The main goals were to check safety and find the best dose, and to see if the combination could shrink tum…

This study tested a shorter, higher-dose radiation treatment given before surgery for soft tissue sarcoma in the arms, legs, or chest wall. 35 adults with early-stage sarcoma took part to see if this approach was safe and could control the cancer. The goal was to reduce side effe…

This study tested a two-step treatment for people with advanced soft tissue sarcoma that had stopped responding to standard therapy. First, a drug called LTX-315 was injected into a tumor to attract immune cells. Then, that tumor was removed, and the immune cells were grown in a …

This study tested a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, in 59 teenagers and young adults whose sarcoma (a type of bone or soft tissue cancer) had come back or was not responding to standard treatment. The main goals were to see if the drug combo…

This study tested whether adding the drug fluzoparil to radiation therapy before surgery is safe and effective for people with soft tissue sarcoma in the arms, legs, or trunk. Fifty-two adults took part. The main goal was to see how many had major wound problems within 4 months a…

This study looked at 53 adults with advanced soft tissue or uterine sarcoma who had stable disease or responded after six cycles of trabectedin. Half continued the drug, while the other half took a break (drug holiday). The goal was to see which approach better delayed cancer gro…

This early-phase trial tested whether adding the drug avelumab (compound 451238) to radiation therapy is safe for people with advanced soft-tissue sarcoma that has spread. Twelve adults with at least two tumors not curable by standard treatments took part. The main goal was to ch…

This study tested a drug called ADI-PEG 20 combined with two chemotherapy drugs (gemcitabine and docetaxel) in 98 people with advanced soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer. The goal was to see if adding ADI-PEG 20, which starves cancer cel…

This early-phase trial tested a combination of two drugs—trabectedin and durvalumab—in 40 people with advanced soft-tissue sarcoma or ovarian cancer that had not responded to prior treatments. The main goal was to find the safest dose and check for early signs of tumor shrinkage.…

This study looked at how the anti-nausea medication aprepitant changes the amount of the chemotherapy drug ifosfamide in the blood of people with soft tissue sarcoma. 59 patients receiving doxorubicin and ifosfamide were followed for two treatment cycles. The goal was to see if a…

This study tested whether it is possible to quickly analyze the DNA of tumors from 24 adults with advanced soft-tissue sarcoma or colorectal cancer. The goal was to see how long it takes to get a complete genetic report back to the doctor. The study did not test a new treatment, …

This study looked at whether advanced genetic testing (called NGS) can be done quickly enough to help guide treatment choices for people with advanced soft-tissue sarcoma. About 600 adults with this rare cancer took part. The main goal was to see if the test results could be deli…